ArticleTransplantation and cellular therapy2026
PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The optimal graft-versus-host disease (GVHD) prophylaxis strategy for 7/8 human leukocyte antigen (HLA)-mismatched unrelated donor (MMUD) hematopoietic cell transplantation (HCT) has not been established. We performed a secondary analysis of a publicly available Center for International Blood and Marrow Transplant Research (CIBMTR) dataset (P-5891) including adults undergoing first 7/8 MMUD HCT between 2017 and 2021. Patients were stratified by GVHD prophylaxis: anti-thymocyte globulin (ATG) with calcineurin inhibitor (CNI) and methotrexate (n = 221), or post-transplant cyclophosphamide (PTCy) with CNI and mycophenolate mofetil (n = 613). PTCy was associated with lower grade II-IV acute GVHD (30.7% versus 50.3%; P < .001) and grade III-IV acute GVHD (7.7% versus 23.8%; P < .001). Nonrelapse mortality (NRM) at 24 months was 17.2% versus 35.1% (P < .001). Rates of moderate-severe chronic GVHD and relapse were comparable. GVHD-free/relapse-free survival (GRFS) at 24 months was 44.9% versus 26.7% (P < .001), and overall survival (OS) at 24 months was 63.9% versus 46.6% (P < .001). On multivariable analysis, PTCy was independently associated with improved GRFS (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.48-0.72; P < .001), lower NRM (HR 0.44, 95% CI 0.32-0.60; P < .001), and improved OS (HR 0.60, 95% CI 0.44-0.72; P < .001), without an increase in relapse risk (HR 1.07, 95% CI 0.77-1.48; P = .68). In this registry-based analysis, PTCy-based prophylaxis was associated with improved OS, NRM, and GRFS compared with ATG-based prophylaxis in 7/8 MMUD HCT. Prospective studies comparing these strategies specifically in MMUD recipients are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.